For new memory symptoms in 2026, start with medical evaluation and an FDA-cleared blood test, not tau PET. Tauklarify (florquinitau F-18 injection, formerly MK-6240) is a brain PET tracer that maps tau tangles in adults with cognitive impairment evaluated for Alzheimer's. Blood tests check amyloid-related signals in blood to guide next steps, while tau PET adds detail about tau pathology later. Tau means a protein that can form tangles inside brain cells, and PET means a scan that uses a small amount of tracer to make pathology visible.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does each test measure?
- Can a good blood test replace PET?
- When does Tauklarify add value?
- What limits should families understand?
- What should you do about new symptoms?
What does each test measure?
Blood tests measure blood markers linked to Alzheimer's pathology and estimate the likelihood of amyloid buildup in the brain. Three cleared options help clinics match the test to age and setting. Practical Neurology and Labcorp reported in August 2025 that Fujirebio Lumipulse G pTau217/beta-Amyloid 1-42 plasma ratio was cleared May 16, 2025 for symptomatic adults, with about 97 percent negative and 93 percent positive predictive value versus PET or spinal fluid. NeurologyLive, reporting Roche's news release, said the Roche Elecsys pTau217 test was cleared August 24, 2026 for adults 55 and older with cognitive signs for both rule-in and rule-out of amyloid pathology in primary and specialty care NeurologyLive's report on the Roche clearance.
NeurologyLive also reported an August 2026 clearance for C2N PrecivityAD2 for symptomatic adults 40 and older, using mass spectrometry of Aβ42/40 plus p-tau217 ratio with 97.6 percent positive and 93.1 percent negative predictive value versus PET or spinal fluid. Tau PET measures something different. The Society of Nuclear Medicine and Molecular Imaging notes Tauklarify binds tau tangles and complements amyloid PET rather than replacing amyloid testing. It is the second FDA-approved tau tracer alongside Tauvid, so its role is staging tau spread after amyloid status is clearer.
Can a good blood test replace PET?
Sometimes, but accuracy thresholds decide. Patient Care, reporting the Alzheimer's Association 2025 guideline, said tests with at least 90 percent sensitivity and 90 percent specificity may substitute for amyloid PET or spinal-fluid testing the guideline summary. Tests with at least 90 percent sensitivity and 75 percent specificity may triage, with PET or spinal-fluid confirmation afterward.
For families, that means the lab number alone does not set the diagnosis. A high-accuracy result can reduce the need for a scan, while a triage-level, positive, or intermediate result points toward confirmation. Ask the clinic which category its test falls into and what cutoff it uses.
When does Tauklarify add value?
Tauklarify helps when the clinical question is specifically about tau tangles after initial evaluation. Enigma Biomedical USA said in its August 14, 2026 press release that FDA approved Tauklarify for brain PET in adults with cognitive impairment evaluated for Alzheimer's to identify tau neurofibrillary tangle pathology the FDA approval announcement. That makes it a mapping tool for tau, not a first screen for forgetfulness.
In practice, it can clarify Alzheimer's evaluation when amyloid evidence, history, and cognitive testing point that way but tau burden remains uncertain. Because it complements amyloid PET, clinicians may use amyloid information first, then add tau PET to understand disease stage or trial eligibility. A memory clinic referral is the usual path to that decision.
What limits should families understand?
A scan alone does not confirm or exclude tau pathology, and safety and effectiveness are not established for non-Alzheimer tauopathies. Practical Neurology summarized these Tauklarify limits in August 2026 and noted blood tests are not standalone diagnostics and can return intermediate results needing PET or spinal-fluid confirmation Practical Neurology's summary of the approval.
That matters for expectations. A negative blood result does not guarantee normal cognition, and a positive result does not prove Alzheimer's by itself. Tau PET also does not sort out every dementia that involves tau, so the clinician must interpret images with history, exam, and other biomarkers.
What should you do about new symptoms?
Practical Neurology described a practical sequence in August 2026: start with history, cognitive testing, and an FDA-cleared blood test. Use a negative result to pursue other causes with your clinician, and use a positive or intermediate result to discuss PET or spinal-fluid confirmation and treatment-trial evaluation. Bring a short symptom timeline to that visit and use these checks:.
- start with history and cognitive testing plus an FDA-cleared blood test
- with a negative result, ask what other medical, sleep, mood, or medication causes to check next
- with a positive or intermediate result, ask about referral for PET or spinal-fluid confirmation and trial evaluation
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: A Source-Checked Briefing for Adults With New Memory Symptoms
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: A Source-Checked Briefing for Adults With New Memory Symptoms
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: A Source-Checked Briefing for Adults With New Memory Symptoms
